. . . "A 6-Month Open-Label, Long-Term Safety Extension Study of Once Daily Ciclesonide HFA Nasal Aerosol (160 \u03BCg) in The Treatment of Perennial Allergic Rhinitis (PAR) in Subjects 12 Years and Older"@en .